Every 10-Q that CAREVIEW COMMUNS INC (CRVW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRVW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRVW filings page.
CareView Communications, Inc. reported higher Q2 2026 revenue of $2.85M and six‑month revenue of $5.04M, both above 2025 levels, driven mainly by new customer sales under its sales‑based and subscription models. Operating performance improved, with operating income of $506,967 in Q2 and $537,811 for the first half of 2026, versus much smaller profits in 2025, and net loss narrowed to $283,663 for Q2 and $1,039,863 year‑to‑date.
Despite better operations and positive operating cash flow of $403,623, the balance sheet remains highly leveraged. At June 30, 2026, CareView had cash of $1.92M, total assets of $5.90M, total liabilities of $49.65M, and a stockholders’ deficit of $43.75M, including a working capital deficit of $44.29M. Notes payable, including related parties, totaled $20.70M, with accrued interest of $24.50M; the long‑standing PDL BioPharma credit facility was again extended to September 30, 2026 and is accounted for as a troubled debt restructuring.
Management states that recurring net losses, large working capital deficit, and dependence on external financing raise substantial doubt about CareView’s ability to continue as a going concern without additional funding. The company also discloses a material weakness in internal control over financial reporting related to technical accounting matters, though it believes the reported financial statements are fairly presented.
CareView Communications, Inc. reported a first-quarter 2026 net loss of $756,200 on revenue of $2,191,342, with revenue slightly below the prior year as lower first-year software bundle revenue offset modest subscription growth. Operating income turned positive at $30,843, but heavy interest expense kept overall results in a loss.
The balance sheet remains highly leveraged: total assets were $4.8M against total liabilities of $48.4M, including $20.7M of notes payable and $23.7M of accrued interest. Stockholders’ deficit was $43.6M and the working capital deficit was $44.0M as of March 31, 2026.
Cash was $1.4M with operating cash outflows of $126,166 in the quarter. Management concluded that recurring net losses and the sizable working capital deficit raise substantial doubt about the company’s ability to continue as a going concern without additional funding.
The company extended its long‑standing credit agreement with PDL BioPharma via a Fourteenth Amendment, pushing the maturity date to June 30, 2026 while the $20.7M note balance remained unchanged. Management accounted for this as a troubled debt restructuring under ASC 470‑60. CareView also disclosed a material weakness in internal control over financial reporting related to technical accounting, though it believes the financial statements are fairly presented.
CareView Communications (CRVW) filed its Q3 2025 10‑Q, showing modest top‑line growth and narrower losses alongside ongoing balance sheet pressure. Revenue for the quarter was $2,064,535 versus $1,932,382 a year ago, driven primarily by software recognized over time. Operating loss improved to $132,467 from $684,476, and net loss narrowed to $914,214 from $1,470,655. For the nine months, revenue reached $6,682,928 (vs. $6,109,259) with an operating loss of $68,406.
Liquidity remains tight. Cash was $1,731,276 as of September 30, 2025. The company reported a working capital deficit of $42,789,653 and a stockholders’ deficit of $42,391,690, and disclosed substantial doubt about continuing as a going concern. Notes payable totaled $20,700,000 with maturity extended to December 31, 2025; accrued interest payable was $22,094,014. Deferred revenue stood at $3,082,405, scheduled to be recognized over the next periods.
Cash provided by operating activities was $1,033,269 for the nine months, reflecting improved collections and deferred revenue activity while interest expense continued to weigh on results.